Press Releases

Share

Aa-+
  • A New Medical Device to Treat Complex Coronary Disease: A Quebec First for the Montreal Heart Institute

    December 15, 2021

    The Montreal Heart Institute (MHI) announces that the Hemodynamics Service has performed Quebec’s first intervention using an orbital atherectomy system on a patient. This state-of-the-art medical device dilates severely blocked arteries caused by calcium plaques.

    This procedure creates space in the calcified artery for a stent to be installed. This small, expandable tube keeps the artery open and helps the blood flow properly.

    Read more

  • The Montreal Heart Institute Receives $9.35 Million From the Quebec Government to Lead a Major Virtual Clinical Trial Project

    December 13, 2021

    The Montreal Heart Institute (MHI) announces that it has won a request for proposals from the Fonds d’accélération des collaborations en santé (FACS). Pierre Fitzgibbon, Minister of Economic and Innovation, announced today a $9.35 million grant from the Government of Quebec to develop and deploy the project entitled Paradigm Shift in the Conduct of Clinical Trials.

    Read more

  • Fighting gut infections contributes to preventing Crohn’s disease and ulcerative colitis.

    November 11, 2021

    A research team from the Montreal Heart Institute (ICM) has shown that genes present in specific intestinal cells protect against the development of inflammatory bowel diseases (IBD). Published today in the scientific journal Genome Medicine, the study results show that more than a dozen of these genes, which contribute to the development of Crohn’s disease and ulcerative colitis, help fight viral and bacterial infections.

    Read more

  • Dr. Jean-Claude Tardif Receives the Prestigious Margolese National Heart Disorders Prize

    September 10, 2021

    The Montreal Heart Institute (MHI) is proud to announce that Dr. Jean-Claude Tardif has been honoured with the 2021 Margolese National Heart Disorders Prize.

    This prestigious distinction is awarded annually to a Canadian physician or scientist who makes outstanding contributions to heart disorders’ treatment, amelioration, or cure.

    Read more

  • Results of the COLCORONA study published in The Lancet Respiratory Medicine

    May 27, 2021

    Colchicine could be considered as a treatment for non-hospitalized patients diagnosed with COVID-19 by PCR test and at risk of complications.

    Read more

  • BRAIN-AF Study Receives Canadian Institutes of Health Research Grant

    March 16, 2021


    The Montreal Heart Institute (MHI) announces that the BRAIN-AF study has received a $1.4 million grant from the Canadian Institutes of Health Research. Seeking to better understand the effects of cardiovascular disease on the cognitive decline of the brain, the study will be able to recruit participants remotely thanks to this funding.

    Read more

  • New Clinical Trial on Hesperidin

    February 16, 2021


    A natural product to fight symptoms related to COVID-19

    The Montreal Heart Institute (MHI) is launching a new clinical trial to evaluate the effect of hesperidin on symptoms related to COVID-19. This flavonoid naturally found in citrus fruits has distinct properties that may reduce the entry and replication of the SARS-CoV2 virus in the body along with the modulation of inflammatory mediators, thus potentially reducing symptoms and prevent complications from the disease.

    Read more

  • Major scientific breakthrough to treat COVID-19

    January 27, 2021

    UPDATE: COLCORONA study manuscript is now available in the public domain.

    READ THE MANUSCRIPT

    On January 22, 2021, the Montreal Heart Institute announced positive results from COLCORONA trial. These results showed that colchicine is the only effective oral medication for treating non-hospitalized patients.

    Read more

  • A new discovery in heart muscle disease

    January 26, 2021

    This medical breakthrough could help prevent the leading cause of sudden death in young people.

    An international team of researchers co-led by Dr. Rafik Tadros, Cardiologist at the Montreal Heart Institute and Assistant Professor at the Université de Montréal, has identified new genetic traits associated with heart muscle disease (cardiomyopathy). This breakthrough, published today in the prestigious scientific journal Nature Genetics, could have a significant impact in the development of drugs against this disease whose mechanisms are still little known.

    Read more

  • Colchicine reduces the risk of COVID-19-related complications

    January 23, 2021

    Positive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients

    Read more

Pages